Efficacy and Safety of Convalescent Plasma Transfusion Administered as Adjunctive Treatment to Standard Treatment in Moderate, Severe, and/or Critically Ill Patients with COVID-19 in Dr. M. Djamil General Hospital

Irza Wahid; Eifel Faheri; Eka Putra Andani; Fauzar Fauzar; Dia Rofinda Zelly; Widyarman Widyarman; Irvan Medison; Emilzon Taslim; Tuti Handayani

doi:10.3889/oamjms.2021.6779

Authors

Irza Wahid Department of Internal Medicine, Subdivision of Hematology-Oncology, Medical Faculty, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia
Eifel Faheri Department of Internal Medicine, Subdivision of Hematology-Oncology, Medical Faculty, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia
Eka Putra Andani Department of Microbiology, Central Laboratory of Diagnostic and Research of Infectious Diseases, Andalas University, Padang, Indonesia
Fauzar Fauzar Department of Internal Medicine, Subdivision of Pulmonology, Medical Faculty, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia
Dia Rofinda Zelly Department of Clinical Pathology, Medical Faculty, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia
Widyarman Widyarman Head of Blood Bank, Indonesian Red Cross Society, Padang, Indonesia
Irvan Medison Department of Pulmonology, Medical Faculty, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia
Emilzon Taslim Department of Anaesthesiology and Intensive Therapy, Medical Faculty, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia
Tuti Handayani Department of Radiology, Medical Faculty, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6779

Keywords:

Coronavirus disease 2019, Convalescent plasma therapy, C-reactive protein

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2. High mortality rate due to COVID-19 has become a serious health problem globally. At present, there is no definitive therapy for COVID-19.

AIM: The objective of this study is to evaluate convalescent plasma therapy (CPT) in COVID-19 patients.

METHODS: The study was conducted in prospective experimental design with sample population of COVID-19 inpatient in Dr. M. Djamil General Hospital, Padang, isolation ward. This study was involving 20 patients consisted of 10 patients of experimental group who received standard therapy and CPT and 10 patients of control group who received standard therapy only; 10 males and 10 females. Differences in laboratory results in both groups were analyzed by T-test or Mann–Whitney U-test.

RESULTS: Twenty subjects included in this study with average of age 56.50 (9.606) years. The mean of C-reactive protein (CRP) serum of the experimental group on day 1 (CRP +1) after CPT was 17.50 (25.343) while the control group was 77.50 (75.177) with p = 0.028 (p < 0.05). However, there were no differences in sequential organ failure assessment, hemoglobin, leukocyte, platelet, partial pressure of oxygen, D-dimer, procalcitonin, interleukin-6, lactate dehydrogenase, ferritin, aspartate aminotransferase, alanine aminotransferase, urea, creatinine, glomerular filtration rate, bilirubin, cycle threshold values, and chest X-ray finding between both groups.

CONCLUSION: There was a significant difference in CRP +1 between the experimental group and control group, while no significant differences found in other parameters between both groups. As CRP is an inflammatory indicator, CPT showed benefit in reducing inflammation in COVID-19 patient.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20. https://doi.org/10.1056/nejmoa2002032 DOI: https://doi.org/10.1056/NEJMoa2002032

Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4):372. https://doi.org/10.3390/v12040372 PMid:32230900 DOI: https://doi.org/10.3390/v12040372

World Health Organization. Coronavirus Disease 2019 (COVID- 19) Situation Report-77. Geneva: World Health Organization; 2020b.

Kementerian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). 4th ed. Jakarta: Kementerian Kesehatan Republik Indonesia; 2020.

Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-8. https://doi.org/10.1172/jci138003 PMid:32167489 DOI: https://doi.org/10.1172/JCI138003

Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza a (H5N1) infection. N Engl J Med. 2007;357(14):1450-1. https://doi.org/10.1056/nejmc070359 PMid:17914053 DOI: https://doi.org/10.1056/NEJMc070359

Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza a (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-45. https://doi.org/10.1093/cid/ciq106 PMid:21248066 DOI: https://doi.org/10.1093/cid/ciq106

Florescu DF, Kalil AC, Hewlett AL, Schuh AJ, Stroher U, Uyeki TM, et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis. 2015;61(6):969-73. https://doi.org/10.1093/cid/civ395 PMid:25991468 DOI: https://doi.org/10.1093/cid/civ395

Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015;61(4):496-502. https://doi.org/10.1093/cid/civ334.12 PMid:25904375 DOI: https://doi.org/10.1093/cid/civ334

Van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in guinea. N Engl J Med. 2016;374:33-42. https://doi.org/10.1056/nejmoa1511812 DOI: https://doi.org/10.1056/NEJMoa1511812

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020;117(17):9490-6. https://doi.org/10.1073/pnas.2004168117 PMid:32253318 DOI: https://doi.org/10.1073/pnas.2004168117

Xia X, Li K, Wu X, Wang Z, Zhu M, Huang B, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020;136(6):755-9. https://doi.org/10.1182/blood.2020007079 PMid:32573724 DOI: https://doi.org/10.1182/blood.2020007079

Hu X, Hu C, Jiang D, Zuo Q, Li Y, Wang Y, et al. Effectiveness of convalescent plasma therapy for COVID-19 patients in Hunan, China. Dose Response. 2020;18(4):1-12. https://doi.org/10.1177/1559325820979921 PMid:33402882 DOI: https://doi.org/10.1177/1559325820979921

Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA. 2020;324(5):460-70. https://doi.org/10.1001/jama.2020.10044 PMid:32492084 DOI: https://doi.org/10.1001/jama.2020.12607

Simonovich VA, Pratx B, Scibona P, Beruto MV, Vallone MG, Vazquez C, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med. 2020;384:619-29. https://doi.org/10.1056/NEJMoa2031304 DOI: https://doi.org/10.1056/NEJMoa2031304

Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicenter randomized controlled trial (PLACID Trial). BMJ. 2020;371:m3939. https://doi.org/10.1136/bmj.m3939 PMid:33093056 DOI: https://doi.org/10.1136/bmj.m3939